BL
FULC icon

BFSG LLC’s Fulcrum Therapeutics FULC Stock Holding History

BFSG LLC’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,510
Closed -$15.6K – 645
2024
Q2 		$15.6K Buy
2,510
+1,300
+107% +$9.85K ﹤0.01% 441
2024
Q1 		$11.4K Buy
+1,210
New +$10.8K ﹤0.01% 487

Other funds holding FULC

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BFSG LLC's FULC Position: Q3 2024 in Review

BFSG LLC sold out of Fulcrum Therapeutics (FULC) in Q3 2024, closing a stake of 2,510 shares — an estimated $15.6K sold.

BFSG LLC first reported a position in FULC in Q1 2024 and held it in 2 quarters. The position peaked at $15.6K in Q2 2024. 130 funds tracked by Wall St. Rank hold FULC as of Q3 2024.

  • BFSG LLC reported no remaining Fulcrum Therapeutics position as of Q3 2024 after selling out during the quarter.
  • BFSG LLC sold 2,510 Fulcrum Therapeutics shares in Q3 2024, an estimated $15.6K.
  • BFSG LLC first reported a position in Fulcrum Therapeutics in Q1 2024 and held it in 2 quarters.
  • BFSG LLC's Fulcrum Therapeutics position peaked at $15.6K in Q2 2024.
  • 130 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q3 2024.

Based on BFSG LLC's 13F filing for Q3 2024, filed 16 Oct 2024.